Gait Analysis and Upper Limb Evaluation Using Syde Device in Adults with Neurological or Metabolic Movement Disorders

What this Trial Is About

Researchers are studying adult patients with neurological or metabolic diseases that affect movement, including neuromuscular disorders and obesity. This observational study at the Centre de Référence Liégeois des Maladies Neuromusculaires in Belgium plans to enroll 300 ambulant adults. The goal is to gather natural history data and evaluate digital mobility outcomes such as the 95th centile of stride velocity (SV95C) as objective markers for future clinical trials, building on previous findings in Duchenne muscular dystrophy. Participants will wear a Syde® device, a wearable magneto-inertial sensor worn on the wrist or ankle, to continuously monitor motor activity in daily life for up to two years (six months for diseases affecting the neuromuscular junction). Standardized clinical tests—including timed walking, stair climbing, rising from the floor, muscle strength measurements, and cognitive assessments—will be performed every six months. Patients will also complete a Patient Global Impression of Change questionnaire at these visits. Those who lose the ability to walk during the study will continue with adapted assessments. During the study, patients will be regularly evaluated through physical and motor function tests, strength measurements using MyoTools, and various clinical rating scales tailored to their conditions. Continuous data from the Syde® device will be compared to these clinical assessments to understand motor function better. The primary outcome measure is the 95th centile of stride velocity, recorded every six months for up to two years. This comprehensive monitoring aims to support the development of sensitive and meaningful digital endpoints for use in future therapeutic trials targeting movement disorders.

Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology